Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011)
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alzheimer's disease is a devastating neurodegenerative disorder for which no disease-modifying therapy exists. The amyloid hypothesis, which implicates Aβ as the toxin initiating a biological cascade leading to neurodegeneration, is the most prominent theory concerning the underlying cause of the disease. BACE1 is one of two aspartyl proteinases that generate Aβ, thus inhibition of BACE1 has the potential to ameliorate the progression of Alzheimer's disease by abating the production of Aβ. AREAS COVERED: This review chronicles small-molecule BACE1 inhibitors as described in the patent literature between 2006 and 2011 and their potential use as disease-modifying treatments for Alzheimer's disease. Over the past half a dozen years, numerous BACE1 inhibitors have been published in the patent applications, but often these contain a paltry amount of pertinent biological data (e.g. potency, selectivity, and efficacy). Fortunately, numerous relevant publications containing important data have appeared in the journal literature during this period. The goal in this effort was to create an amalgam of the two records to add value to this review. EXPERT OPINION: The pharmaceutical industry has made tremendous progress in the development of small-molecule BACE1 inhibitors that lower Aβ in the central nervous system. Assuming the amyloid hypothesis is veracious, we anticipate a disease-modifying therapy to combat Alzheimer's disease is near.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedRETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992 · cited 1×
“The first and rate-limiting step of Ab peptide production is the cleavage of APP by BACE1 [10] which releases the soluble N-terminal APP fragment (sAPPb) (sAPPb initiates a cascade event which can ultimately lead to apoptosis) [44] leaving behind the C99 fragment which is subsequently cleaved by g-secretase to liberat…”
BackgroundRetractedQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“The pathology of this neurodegenerative disorder manifests itself with the presence of extraneuronal aggregation of plaques composed of b-amyloid peptides (Ab) [6] and intracellular neurofibrillary tangles (NFTs) [7], aggregates of aberrantly hyperphosphorylated tau proteins, which are common to numerous neurodegenera…”
BackgroundLee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“The pathology of this neurodegenerative disorder manifests itself with the presence of extraneuronal aggregation of plaques composed of b-amyloid peptides (Ab) [6] and intracellular neurofibrillary tangles (NFTs) [7], aggregates of aberrantly hyperphosphorylated tau proteins, which are common to numerous neurodegenera…”
BackgroundBallard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“Fibrillization of soluble Ab could actually be a mechanism of detoxification [55] since synaptotoxicity can precede plaque formation in mice [56-58].”
Background
Cited by
Targeting the β secretase BACE1 for Alzheimer's disease therapy
Yan, R., & Vassar, R. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 630
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410
Yuan, J., Venkatraman, S., Zheng, Y., McKeever, B. M., Dillard, L. W., & Singh, S. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301659n · Cited by 135
Devraj, K., Poznanovic, S., Spahn, C., Schwall, G., Harter, P. N., Mittelbronn, M., Antoniello, K., Paganetti, P., Muhs, A., Heilemann, M., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15606463 · Cited by 63
BACE2 suppression in mice aggravates the adverse metabolic consequences of an obesogenic diet
Díaz-Catalán, D., Alcarraz-Vizán, G., Castaño, C., de Pablo, S., Rodríguez-Comas, J., Fernández-Pérez, A., Vallejo, M., Ramírez, S., Claret, M., Parrizas, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101251 · Cited by 10
Metadata
- Authors
- Probst, G., & Xu, Y.-Z.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2012-04-19
- Volume
- 22
- Issue
- 5
- Pages
- 511-540
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W1967164727
- Cited by
- 76
- References
- 51
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011). https://app.cochat.ai/papers/10.1517/13543776.2012.681302
- The paper
- Probst, G., & Xu, Y.-Z. (2012). Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011). Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.2012.681302
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.